152 related articles for article (PubMed ID: 18819944)
1. Problems with GH assays and strategies toward standardization.
Bidlingmaier M
Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S41-4. PubMed ID: 18819944
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone assays: current methodologies and their limitations.
Bidlingmaier M; Strasburger CJ
Pituitary; 2007; 10(2):115-9. PubMed ID: 17429592
[TBL] [Abstract][Full Text] [Related]
3. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.
Bidlingmaier M; Freda PU
Growth Horm IGF Res; 2010 Feb; 20(1):19-25. PubMed ID: 19818659
[TBL] [Abstract][Full Text] [Related]
4. Laboratory assessment of GH.
Strasburger CJ
Growth Horm IGF Res; 1998 Feb; 8 Suppl A():41-6. PubMed ID: 10993590
[TBL] [Abstract][Full Text] [Related]
5. Human growth hormone (GH) immunoassay: standardization and clinical implications.
Carrozza C; Lapolla R; Canu G; Annunziata F; Torti E; Baroni S; Zuppi C
Clin Chem Lab Med; 2011 May; 49(5):851-3. PubMed ID: 21361855
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of growth hormone deficiency is affected by calibrators used in GH immunoassays.
Meazza C; Albertini R; Pagani S; Sessa N; Laarej K; Falcone R; Bozzola E; Calcaterra V; Bozzola M
Horm Metab Res; 2012 Nov; 44(12):900-3. PubMed ID: 22674475
[TBL] [Abstract][Full Text] [Related]
7. Confusion in clinical laboratory GH and IGF-I reports.
Melmed S
Pituitary; 1999 Aug; 2(2):171-2. PubMed ID: 11081168
[No Abstract] [Full Text] [Related]
8. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
Manolopoulou J; Alami Y; Petersenn S; Schopohl J; Wu Z; Strasburger CJ; Bidlingmaier M
Clin Chem; 2012 Oct; 58(10):1446-56. PubMed ID: 22908135
[TBL] [Abstract][Full Text] [Related]
9. Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly.
Morrison KM; Bidlingmaier M; Stadler S; Wu Z; Skriver L; Strasburger CJ
Eur J Endocrinol; 2007 Mar; 156(3):331-9. PubMed ID: 17322493
[TBL] [Abstract][Full Text] [Related]
10. Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.
Bonert V; Carmichael J; Wu Z; Mirocha J; Perez DA; Clarke NJ; Reitz RE; McPhaul MJ; Mamelak A
Pituitary; 2018 Feb; 21(1):65-75. PubMed ID: 29218459
[TBL] [Abstract][Full Text] [Related]
11. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
13. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
14. Detecting and solving the interference of pregnancy serum, in a GH immunometric assay.
Dias ML; Vieira JG; Abucham J
Growth Horm IGF Res; 2013; 23(1-2):13-8. PubMed ID: 23206731
[TBL] [Abstract][Full Text] [Related]
15. Differences in serum GH cut-off values for pharmacological tests of GH secretion depend on the serum GH method. Clinical validation from the growth velocity score during the first year of treatment.
Chaler EA; Rivarola MA; Guerci B; Ciaccio M; Costanzo M; Travaglino P; Maceiras M; Pagani S; Meazza C; Bozzola E; Barberi S; Bozzola M; Belgorosky A
Horm Res; 2006; 66(5):231-5. PubMed ID: 16912509
[TBL] [Abstract][Full Text] [Related]
16. Standardization of immunoassays.
Masseyeff RF
Ann Ist Super Sanita; 1991; 27(3):427-36. PubMed ID: 1725576
[TBL] [Abstract][Full Text] [Related]
17. Factors modifying growth hormone estimates in immunoassays.
Fisker S; Orskov H
Horm Res; 1996; 46(4-5):183-7. PubMed ID: 8950618
[TBL] [Abstract][Full Text] [Related]
18. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population.
Granada ML; Ulied A; Casanueva FF; Pico A; Lucas T; Torres E; Sanmartí A
Clin Endocrinol (Oxf); 2008 Jun; 68(6):942-50. PubMed ID: 17980002
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
Arafat AM; Möhlig M; Weickert MO; Perschel FH; Purschwitz J; Spranger J; Strasburger CJ; Schöfl C; Pfeiffer AF
J Clin Endocrinol Metab; 2008 Apr; 93(4):1254-62. PubMed ID: 18171702
[TBL] [Abstract][Full Text] [Related]
20. Performance evaluation of a fully automated immunoassay for the detection of human growth hormone on the Elecsys immunoassay system.
Van Helden J; Hermsen D; Von Ahsen N; Bidlingmaier M
Clin Lab; 2014; 60(10):1641-51. PubMed ID: 25651709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
